review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1080/02841860151116367 |
P698 | PubMed publication ID | 11441937 |
P50 | author | Bengt Glimelius | Q30830855 |
Peter Nygren | Q66206118 | ||
P2093 | author name string | SBU-group. Swedish Council of Technology Assessment in Health Care | |
P Ragnhammar | |||
L Hafström | |||
P433 | issue | 2-3 | |
P921 | main subject | colorectal carcinoma | Q25493920 |
colorectal cancer | Q188874 | ||
chemotherapy | Q974135 | ||
P304 | page(s) | 282-308 | |
P577 | publication date | 2001-01-01 | |
P1433 | published in | Acta Oncologica | Q326164 |
P1476 | title | A systematic overview of chemotherapy effects in colorectal cancer | |
P478 | volume | 40 |
Q28533805 | 2-deprenyl-rheediaxanthone B isolated from Metaxya rostrata induces active cell death in colorectal tumor cells |
Q34227755 | A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer |
Q44473114 | A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. |
Q36109706 | A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients |
Q34798367 | A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study |
Q33390290 | A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver |
Q33405667 | A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases |
Q37341713 | A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer |
Q37078321 | A study of lymph node ratio in stage IV colorectal cancer |
Q24242231 | Adjuvant Therapy for completely resected Stage II Colon Cancer |
Q36303863 | Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in Europe? |
Q53313028 | Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). |
Q36097096 | Bax expression is a candidate prognostic and predictive marker of colorectal cancer |
Q36106736 | Benefit-risk assessment of irinotecan in advanced colorectal cancer |
Q43700721 | Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis |
Q37059607 | Calnexin, an ER-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer |
Q34388693 | Chemoradiotherapy for rectal cancer--is there an optimal combination? |
Q90366618 | Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis |
Q53085418 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. |
Q34390831 | Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection |
Q38930537 | Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity |
Q36691267 | ColoFinder: a prognostic 9-gene signature improves prognosis for 871 stage II and III colorectal cancer patients |
Q60300873 | Colorectal cancer survival rates in Ghana: A retrospective hospital-based study |
Q84644669 | Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study |
Q40469387 | Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine. |
Q46042915 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study |
Q31095892 | Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues |
Q36944056 | Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer |
Q36832121 | Current role of antibody therapy in patients with metastatic colorectal cancer. |
Q35047600 | Current treatment for liver metastases from colorectal cancer |
Q55456514 | Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer. |
Q37677564 | Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy |
Q49226934 | Elevated Adenylyl Cyclase 9 Expression Is a Potential Prognostic Biomarker for Patients with Colon Cancer. |
Q40629291 | Enhanced green fluorescent protein-transfection of murine colon carcinoma cells: key for early tumor detection and quantification |
Q39395473 | Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples |
Q36073367 | Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. |
Q39978242 | Expression of integrin-linked kinase is increased in differentiated cells |
Q35669537 | Follow-up after colorectal cancer surgery |
Q47606349 | Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature |
Q35006757 | Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer |
Q53881839 | Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. |
Q38450906 | Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin 20 gene and protein expression |
Q36694446 | Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study |
Q46772923 | In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer |
Q39710105 | Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin |
Q37394656 | Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. |
Q24200737 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer |
Q24234555 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer |
Q24186145 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer |
Q35666090 | Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy |
Q37975508 | Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status |
Q44767634 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer |
Q35111182 | Palliative Treatment of Patients with Colorectal Cancer |
Q43898953 | Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study |
Q26830336 | Peptide Vaccine Therapy in Colorectal Cancer |
Q33388487 | Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement |
Q33392260 | Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement |
Q74574102 | Pre- or postoperative radiotherapy in rectal cancer--more to learn? |
Q37728678 | Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer |
Q38377842 | Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. |
Q39034233 | Proteomic analysis identifies proteins associated with curcumin-enhancing efficacy of irinotecan-induced apoptosis of colorectal cancer LOVO cell |
Q48489461 | Quality of Life assessment through the EORTC questionnaires of colorectal cancer patients in advanced disease stages |
Q79846295 | Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil |
Q37327269 | Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells |
Q35737399 | Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions |
Q40007032 | SNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment |
Q35771162 | Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas |
Q40610463 | Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. |
Q44767638 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer |
Q34399187 | Six-year experience of a nurse-led colorectal cancer follow-up clinic. |
Q43636087 | Survival after elective surgery for colonic cancer in Denmark |
Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
Q36217126 | Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report |
Q37508586 | The Management and Prognostic Prediction of Adenocarcinoma of Appendix |
Q52591422 | The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. |
Q81075281 | The mesenteric and antimesenteric location of colorectal cancer: the relationship with lymph nodes |
Q34558185 | The role of radiotherapy in rectal cancer |
Q34805943 | The timing of introduction of pharmaceutical innovations in seven European countries |
Q44667185 | The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study |
Q38441178 | Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up |
Q45053701 | Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer |
Q50790977 | True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function. |
Q58121936 | Vitamin C in the critically ill - indications and controversies |
Q38152887 | Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer |
Q78316496 | [Measure of quality of life in patients with metastatic colorectal cancer: techniques and main results] |
Q52809418 | [Update on colon cancer 2017]. |
Q53743905 | [Use of the term "radiosurgery" in scientific publications]. |
Q37582210 | miR-217 regulates tumor growth and apoptosis by targeting the MAPK signaling pathway in colorectal cancer |
Q47805359 | miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells |
Search more.